Global Guillain-Barre Syndrome (GBS) Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
길랭 바레 증후군(GBS) 시장의 세계 수요는 2023년 6억 7,262만 달러에서 2032년 10억 5,424만 달러에 육박하는 시장 규모에 도달할 것으로 추정되며, 2024년까지 연평균 5.12%의 CAGR을 기록할 것으로 예상됩니다.
길랭 바레 증후군(GBS)은 면역계가 말초신경을 표적으로 삼아 근력 약화와 마비를 일으키는 희귀한 자가면역질환입니다. 증상은 종종 다리의 무감각과 쇠약으로 시작되며, 진행되면 전신에 영향을 미칩니다. 일반적으로 감염이 GBS를 유발하며, 회복을 위해서는 면역요법 및 물리치료와 같은 치료가 필요합니다. 더 나은 결과를 얻으려면 조기 진단과 개입이 필수적입니다.
시장 역학
길랭 바레 증후군(GBS) 시장은 이 질환의 진단, 치료 및 연구에 영향을 미치는 다양한 요인에 의해 주도되고 있습니다. 길랭 바레 증후군(GBS)에 대한 의료진과 일반 대중의 인식이 높아지면서 조기 진단과 조기 개입이 가능해졌습니다. 지카 바이러스 및 최근 COVID-19와 같은 감염성 질환과 관련하여 GBS의 유병률이 증가함에 따라 이 증후군에 대한 관심이 증가하고 있습니다. 의학 연구와 기술의 발전으로 GBS에 대한 이해가 깊어지면서 보다 효과적인 치료법과 치료법이 개발되고 있으며, GBS의 주요 치료법인 면역글로불린 요법과 혈장 페레시스 요법은 큰 진전을 이루며 그 효과와 접근성이 향상되었습니다.
희귀질환 연구를 위한 정부 및 민간 자금 지원도 기술 혁신과 새로운 치료 옵션을 촉진함으로써 GBS 시장의 성장을 뒷받침하고 있습니다. 또한, 전문 의료 시설의 증가와 첨단 진단 도구의 가용성 또한 GBS의 관리 개선에 기여하고 있습니다. 의료 서비스 제공자, 연구자, 환자 지원 단체의 협력은 길랭 바레 증후군(GBS)에 대한 인식을 높이고 환자들을 지원하는 데 필수적이며, 이는 시장 성장에 기여하고 있습니다. 그러나 일부 지역의 낮은 인지도와 진단 지연은 향후 몇 년 동안 시장 성장에 걸림돌이 될 수 있습니다.
이 조사 보고서는 Porter's Five Forces 모델, 시장 매력도 분석, 밸류체인 분석을 다루고 있습니다. 이러한 도구는 산업 구조를 명확하게 파악하고 세계 수준에서 경쟁의 매력을 평가하는 데 도움이됩니다. 또한 이러한 도구는 길랭 바레 증후군(GBS) 세계 시장에서 각 부문을 포괄적으로 평가할 수 있습니다. 길랭 바레 증후군(GBS) 산업의 성장과 동향은 이 조사에 대한 전체적인 접근 방식을 제공합니다.
지역별 분석
이 섹션에서는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카의 길랭 바레 증후군(GBS) 시장의 현재 및 미래 수요를 강조하는 지역 전망을 다룹니다. 또한, 이 보고서는 모든 주요 지역의 개별 응용 부문의 수요, 추정 및 예측에 초점을 맞추고 있습니다.
맞춤형 요구사항이 있는 경우, 저희에게 연락주시기 바랍니다. 당사의 조사팀은 고객의 요구에 따라 맞춤형 보고서를 제공할 수 있습니다.
목차
제1장 서문
제2장 주요 요약
제3장 길랭 바레 증후군(GBS) - 산업 분석
- 소개 : 시장 역학
- 시장 성장 촉진요인
- 시장 성장 억제요인
- 시장 기회
- 산업 동향
- Porter's Five Forces 분석
- 시장 매력도 분석
제4장 밸류체인 분석
- 밸류체인 분석
- 원재료 분석
- 원재료 리스트
- 원재료 제조업체 리스트
- 주요 원재료 가격 동향
- 잠재적 바이어 리스트
- 마케팅 채널
- 직접 마케팅
- 간접 마케팅
- 마케팅 채널 발전 동향
제5장 길랭 바레 증후군(GBS) 세계 시장 분석 : 치료 유형별
- 치료 유형별 개요
- 실적 데이터와 예측 데이터
- 치료 유형별 분석
- 1차 치료(면역글로불린 정맥주사(IVIG), 혈장 교환(혈장분리교환술))
- 보조 치료
제6장 길랭 바레 증후군(GBS) 세계 시장 분석 : 유형별
- 유형별 개요
- 실적 데이터와 예측 데이터
- 유형별 분석
- 급성 염증성 탈수초성 다발신경병증(AIDP)
- 만성 염증성 탈수초성 다발신경병증(CIDP)
- 밀러 피셔 증후군(MFS)
- 급성 운동 축삭 신경병증(AMAN)
- 기타 유형
제7장 길랭 바레 증후군(GBS) 세계 시장 분석 : 성별
- 성별 개요
- 실적 데이터와 예측 데이터
- 성별 분석
- 남성
- 여성
제8장 길랭 바레 증후군(GBS) 세계 시장 분석 : 연령층별
- 연령층별 개요
- 실적 데이터와 예측 데이터
- 연령층별 분석
- 20세 미만
- 21-40세
- 41-59세
- 60세 이상
제9장 길랭 바레 증후군(GBS) 세계 시장 분석 : 최종사용자별
- 최종사용자별 개요
- 실적 데이터와 예측 데이터
- 최종사용자별 분석
- 병원
- 진료소
- 재활 센터
- 기타 최종사용자
제10장 길랭 바레 증후군(GBS) 세계 시장 분석 : 지역별
- 지역별 전망
- 소개
- 북미의 매출 분석
- 개요, 실적과 예측
- 북미 : 부문별
- 북미 : 국가별
- 미국
- 캐나다
- 멕시코
- 유럽 매출 분석
- 개요, 실적과 예측
- 유럽 : 부문별
- 유럽 : 국가별
- 영국
- 프랑스
- 독일
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양 매출 분석
- 개요, 실적과 예측
- 아시아태평양 : 부문별
- 아시아태평양 : 국가별
- 중국
- 인도
- 일본
- 한국
- 호주
- 동남아시아
- 기타 아시아태평양
- 라틴아메리카 매출 분석
- 개요, 실적과 예측
- 라틴아메리카 : 부문별
- 라틴아메리카 : 국가별
- 브라질
- 아르헨티나
- 페루
- 칠레
- 기타 라틴아메리카
- 중동 및 아프리카 매출 분석
- 개요, 실적과 예측
- 중동 및 아프리카 : 부문별
- 중동 및 아프리카 : 국가별
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
제11장 길랭 바레 증후군(GBS) 기업 경쟁 상황
- 길랭 바레 증후군(GBS) 시장 경쟁
- 제휴, 협력, 합의
- 인수합병
- 신제품 출시
- 기타 개발
제12장 기업 개요
- 상위 기업의 시장 점유율 분석
- 시장 집중도
- AbbVie Inc.
- Biogen Inc.
- Cadila Healthcare Limited
- CSL Behring LLC
- F.Hoffmann-La Roche Ltd.
- GSK Plc
- Grifols SA
- LGM Pharmaceuticals Inc.
- Merck & Co. Inc.
- Octapharma AG
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
ksm
The global demand for Guillain-Barre Syndrome (GBS) Market is presumed to reach the market size of nearly USD 1054.24 Million by 2032 from USD 672.62 Million in 2023 with a CAGR of 5.12% under the study period 2024-2032.
Guillain-Barre syndrome (GBS) is an uncommon autoimmune disorder in which the immune system targets the peripheral nerves, leading to muscle weakness and paralysis. Symptoms often begin with tingling & weakness in the legs and can progress to affect the entire body. An infection typically triggers GBS and requires medical treatment such as immunotherapy and physical therapy for recovery. Early diagnosis and intervention are vital for better outcomes.
MARKET DYNAMICS
The guillain-barre syndrome (GBS) market is driven by various factors influencing the diagnosis, treatment, and research associated with this condition. Spurring awareness among healthcare professionals and the public about guillain-barre syndrome (GBS)has led to earlier diagnosis and intervention, which is crucial for better patient outcomes. The rising prevalence of GBS, often linked to infections like the Zika virus and, more recently, COVID-19, has heightened the focus on this syndrome. Medical research and technology advances have improved the understanding of GBS, leading to more effective treatments and therapies. Immunoglobulin therapy and plasmapheresis, the primary treatments for GBS, have seen significant advancements, enhancing their efficacy and accessibility.
Government and private funding for rare disease research also supports the growth of the GBS market by fostering innovation and new treatment options. Furthermore, the increasing number of specialized healthcare facilities and the availability of advanced diagnostic tools contribute to the improved management of GBS. Collaborative efforts among healthcare providers, researchers, and patient advocacy groups are vital in driving awareness and supporting those affected by guillain-barre syndrome (GBS), propelling the market growth. However, limited awareness and late diagnosis in certain regions may challenge the market growth in the coming years.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Guillain-Barre Syndrome (GBS). The growth and trends of Guillain-Barre Syndrome (GBS) industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the Guillain-Barre Syndrome (GBS) market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Treatment Type
- First-line Treatment (Intravenous immunoglobulin (IVIG), Plasma exchange (Plasmapheresis))
- Supportive treatment
By Type
- Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Miller Fisher Syndrome (MFS)
- Acute Motor Axonal Neuropathy (AMAN)
- Other Types
By Gender
By Age Group
- Below 20 years
- 21-40 years
- 41-59 years
- 60 and above
By End-user
- Hospitals
- Clinics
- Rehabilitation Centers
- Other end-users
REGIONAL ANALYSIS
This section covers the regional outlook, which accentuates current and future demand for the Guillain-Barre Syndrome (GBS) market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Guillain-Barre Syndrome (GBS) market include AbbVie Inc., Biogen Inc., Cadila Healthcare Limited, CSL Behring LLC, F.Hoffmann-La Roche Ltd., GSK Plc, Grifols SA, LGM Pharmaceuticals Inc., Merck & Co. Inc., Octapharma AG, Pfizer Inc., Takeda Pharmaceutical Company Limited. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1. PREFACE
- 1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology
2. EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3. GUILLAIN-BARRE SYNDROME (GBS) - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Treatment Type
- 3.7.2 Market Attractiveness Analysis By Type
- 3.7.3 Market Attractiveness Analysis By Gender
- 3.7.4 Market Attractiveness Analysis By Age Group
- 3.7.5 Market Attractiveness Analysis By End-user
- 3.7.6 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend
5. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY TREATMENT TYPE
- 5.1. Overview By Treatment Type
- 5.2. Historical and Forecast Data
- 5.3. Analysis By Treatment Type
- 5.4. First-line Treatment (Intravenous immunoglobulin (IVIG), Plasma exchange (Plasmapheresis)) Historic and Forecast Sales By Regions
- 5.5. Supportive treatment Historic and Forecast Sales By Regions
6. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY TYPE
- 6.1. Overview By Type
- 6.2. Historical and Forecast Data
- 6.3. Analysis By Type
- 6.4. Acute Inflammatory Demyelinating Polyneuropathy (AIDP) Historic and Forecast Sales By Regions
- 6.5. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Historic and Forecast Sales By Regions
- 6.6. Miller Fisher Syndrome (MFS) Historic and Forecast Sales By Regions
- 6.7. Acute Motor Axonal Neuropathy (AMAN) Historic and Forecast Sales By Regions
- 6.8. Other Types Historic and Forecast Sales By Regions
7. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY GENDER
- 7.1. Overview By Gender
- 7.2. Historical and Forecast Data
- 7.3. Analysis By Gender
- 7.4. Male Historic and Forecast Sales By Regions
- 7.5. Female Historic and Forecast Sales By Regions
8. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY AGE GROUP
- 8.1. Overview By Age Group
- 8.2. Historical and Forecast Data
- 8.3. Analysis By Age Group
- 8.4. Below 20 years Historic and Forecast Sales By Regions
- 8.5. 21-40 years Historic and Forecast Sales By Regions
- 8.6. 41-59 years Historic and Forecast Sales By Regions
- 8.7. 60 and above Historic and Forecast Sales By Regions
9. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY END-USER
- 9.1. Overview By End-user
- 9.2. Historical and Forecast Data
- 9.3. Analysis By End-user
- 9.4. Hospitals Historic and Forecast Sales By Regions
- 9.5. Clinics Historic and Forecast Sales By Regions
- 9.6. Rehabilitation Centers Historic and Forecast Sales By Regions
- 9.7. Other end-users Historic and Forecast Sales By Regions
10. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY GEOGRAPHY
- 10.1. Regional Outlook
- 10.2. Introduction
- 10.3. North America Sales Analysis
- 10.3.1 Overview, Historic and Forecast Data Sales Analysis
- 10.3.2 North America By Segment Sales Analysis
- 10.3.3 North America By Country Sales Analysis
- 10.3.4 United States Sales Analysis
- 10.3.5 Canada Sales Analysis
- 10.3.6 Mexico Sales Analysis
- 10.4. Europe Sales Analysis
- 10.4.1 Overview, Historic and Forecast Data Sales Analysis
- 10.4.2 Europe By Segment Sales Analysis
- 10.4.3 Europe By Country Sales Analysis
- 10.4.4 United Kingdom Sales Analysis
- 10.4.5 France Sales Analysis
- 10.4.6 Germany Sales Analysis
- 10.4.7 Italy Sales Analysis
- 10.4.8 Russia Sales Analysis
- 10.4.9 Rest Of Europe Sales Analysis
- 10.5. Asia Pacific Sales Analysis
- 10.5.1 Overview, Historic and Forecast Data Sales Analysis
- 10.5.2 Asia Pacific By Segment Sales Analysis
- 10.5.3 Asia Pacific By Country Sales Analysis
- 10.5.4 China Sales Analysis
- 10.5.5 India Sales Analysis
- 10.5.6 Japan Sales Analysis
- 10.5.7 South Korea Sales Analysis
- 10.5.8 Australia Sales Analysis
- 10.5.9 South East Asia Sales Analysis
- 10.5.10 Rest Of Asia Pacific Sales Analysis
- 10.6. Latin America Sales Analysis
- 10.6.1 Overview, Historic and Forecast Data Sales Analysis
- 10.6.2 Latin America By Segment Sales Analysis
- 10.6.3 Latin America By Country Sales Analysis
- 10.6.4 Brazil Sales Analysis
- 10.6.5 Argentina Sales Analysis
- 10.6.6 Peru Sales Analysis
- 10.6.7 Chile Sales Analysis
- 10.6.8 Rest of Latin America Sales Analysis
- 10.7. Middle East & Africa Sales Analysis
- 10.7.1 Overview, Historic and Forecast Data Sales Analysis
- 10.7.2 Middle East & Africa By Segment Sales Analysis
- 10.7.3 Middle East & Africa By Country Sales Analysis
- 10.7.4 Saudi Arabia Sales Analysis
- 10.7.5 UAE Sales Analysis
- 10.7.6 Israel Sales Analysis
- 10.7.7 South Africa Sales Analysis
- 10.7.8 Rest Of Middle East And Africa Sales Analysis
11. COMPETITIVE LANDSCAPE OF THE GUILLAIN-BARRE SYNDROME (GBS) COMPANIES
- 11.1. Guillain-Barre Syndrome (GBS) Market Competition
- 11.2. Partnership/Collaboration/Agreement
- 11.3. Merger And Acquisitions
- 11.4. New Product Launch
- 11.5. Other Developments
12. COMPANY PROFILES OF GUILLAIN-BARRE SYNDROME (GBS) INDUSTRY
- 12.1. Top Companies Market Share Analysis
- 12.2. Market Concentration Rate
- 12.3. AbbVie Inc.
- 12.3.1 Company Overview
- 12.3.2 Company Revenue
- 12.3.3 Products
- 12.3.4 Recent Developments
- 12.4. Biogen Inc.
- 12.4.1 Company Overview
- 12.4.2 Company Revenue
- 12.4.3 Products
- 12.4.4 Recent Developments
- 12.5. Cadila Healthcare Limited
- 12.5.1 Company Overview
- 12.5.2 Company Revenue
- 12.5.3 Products
- 12.5.4 Recent Developments
- 12.6. CSL Behring LLC
- 12.6.1 Company Overview
- 12.6.2 Company Revenue
- 12.6.3 Products
- 12.6.4 Recent Developments
- 12.7. F.Hoffmann-La Roche Ltd.
- 12.7.1 Company Overview
- 12.7.2 Company Revenue
- 12.7.3 Products
- 12.7.4 Recent Developments
- 12.8. GSK Plc
- 12.8.1 Company Overview
- 12.8.2 Company Revenue
- 12.8.3 Products
- 12.8.4 Recent Developments
- 12.9. Grifols SA
- 12.9.1 Company Overview
- 12.9.2 Company Revenue
- 12.9.3 Products
- 12.9.4 Recent Developments
- 12.10. LGM Pharmaceuticals Inc.
- 12.10.1 Company Overview
- 12.10.2 Company Revenue
- 12.10.3 Products
- 12.10.4 Recent Developments
- 12.11. Merck & Co. Inc.
- 12.11.1 Company Overview
- 12.11.2 Company Revenue
- 12.11.3 Products
- 12.11.4 Recent Developments
- 12.12. Octapharma AG
- 12.12.1 Company Overview
- 12.12.2 Company Revenue
- 12.12.3 Products
- 12.12.4 Recent Developments
- 12.13. Pfizer Inc.
- 12.13.1 Company Overview
- 12.13.2 Company Revenue
- 12.13.3 Products
- 12.13.4 Recent Developments
- 12.14. Takeda Pharmaceutical Company Limited
- 12.14.1 Company Overview
- 12.14.2 Company Revenue
- 12.14.3 Products
- 12.14.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies
